Chinese investors lead Grail's $300M series C

Cancer detection company Grail Inc. (Menlo Park, Calif.) raised $300 million in an oversubscribed series C round on May 21. Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital led the round, with participation from fellow new investors Blue Pool Capital, China Merchants Securities, CRF Investment, HuangPu River Capital, ICBC International, Sequoia Capital China and WuXi NextCode Genomics Inc. (Cambridge, Mass.) (see BioCentury, May 25)...